The global autoimmune disease therapeutics market is projected to grow from USD 133 billion in 2025 to USD 255 billion by 2034, with an 8% CAGR. Growth is driven by rising prevalence of autoimmune disorders, increasing adoption of biologics and targeted therapies, advancements in precision medicine, and expanding...
A $1,000 investment in Halozyme Therapeutics made in September 2016 would be worth $9,284.68 as of September 23, 2026, representing an 828.47% gain. The biopharmaceutical company's growth is driven by royalties from its ENHANZE drug delivery technology licensed to major pharma partners. However, biosimilar competition...
DGRO, a smart beta ETF sponsored by BlackRock, provides broad exposure to large-cap dividend growth stocks with a low 0.08% expense ratio and $43.03 billion in assets. The fund has delivered 12.35% year-to-date returns and 16.02% one-year returns with medium risk profile, holding 398 stocks across sectors led by...
The Invesco Nasdaq Biotechnology ETF (IBBQ) offers lower costs (0.19% expense ratio) and higher 1-year returns (44.6%), making it suitable for growth-focused investors willing to accept volatility. The iShares U.S. Healthcare ETF (IYH) provides broader diversification across 100 healthcare holdings with higher dividend...
The psoriatic arthritis market is expected to expand significantly through 2036 driven by emerging late-stage therapies from major pharmaceutical companies. Key drugs in development include tildrakizumab (Sun Pharma), sonelokimab (MoonLake), icotrokinra (Johnson & Johnson), zasocitinib (Takeda), izokibep (Affibody...
The article provides a strategic framework for retirees on fixed incomes to protect their savings while managing inflation risk. It recommends a three-bucket approach: maintaining 12-24 months of expenses in cash/short-term fixed income, holding inflation-beating investments with dividend stocks, and allocating...
Bristol Myers Squibb (BMY) is up 17% this year and trades at a discount to peers despite strong Q2 performance with $12.9B revenue and 153% EPS growth. The company's growth portfolio of newer drugs now accounts for nearly 60% of revenue and grew 15% year-over-year, offsetting concerns about patent expirations on legacy...
AstraZeneca's stock has declined following several late-stage pipeline failures including Wainua in ATTR-CM, Ultomiris in HSCT-TMA, volrustomig in NSCLC, and Etcamah in breast cancer. However, the company maintains a broad pipeline with over 20 expected high-value readouts in the next 18 months, particularly in...
Johnson & Johnson's stock has risen 18.3% in three months, driven by strong Innovative Medicine segment growth (6.2% organic), successful new drug launches (Icotyde, Imaavy, Inlexzo), and progress on talc litigation resolution. The company targets $100 billion in 2026 revenues and expects double-digit growth excluding...
Johnson & Johnson stock gained 1.1% to $270.22 but underperformed the S&P 500's 1.14% gain. The company is expected to report Q3 earnings on October 13, 2026, with projected EPS of $2.96 (up 5.71% YoY) and revenue of $25.36 billion (up 5.71% YoY). However, JNJ trades at a premium valuation with a Forward P/E of 23.05...
The global autoimmune disease therapeutics market is projected to grow from USD 132.75 billion in 2025 to USD 254.60 billion by 2034, at a CAGR of 7.5%. Growth is driven by rising autoimmune disease diagnoses, increased adoption of biologics and targeted oral therapies, biosimilar expansion, and emerging cell and gene...
Amid current market volatility driven by high Treasury yields, elevated oil prices, and inflation concerns, dividend growth stocks offer a historically proven strategy for delivering higher returns with lower volatility. The iShares Core Dividend Growth ETF (DGRO) provides an easy way to invest in companies with at...
The article recommends five resilient stocks suitable for uncertain market conditions: Johnson & Johnson (pharmaceutical and medtech leader with 28 billion-dollar products), Vertex Pharmaceuticals (cystic fibrosis treatment market leader with pipeline expansion), Costco (essential goods retailer with high membership...
The CAR T-cell therapy market for non-Hodgkin's lymphoma is projected to grow at a 7% CAGR from 2026 to 2036, reaching from a 2025 valuation of $3.20 billion across seven major markets. Growth is driven by broader clinical adoption, new indications, earlier-line use, and innovation in autologous and allogeneic...
The global immunotherapy drugs market is experiencing significant growth driven by advances in biotechnology, rising demand for targeted treatments, and expanding therapeutic applications across cancer, autoimmune, and inflammatory diseases. Key growth factors include increasing disease burden, robust drug pipelines,...
The iShares U.S. Pharmaceuticals ETF (IHE) is a passively managed fund offering broad exposure to the Healthcare-Pharma sector with $1.63 billion in assets. The ETF has delivered strong year-to-date returns of 20.69% and 45.67% over the past year, though it carries higher risk with a beta of 0.49 and standard deviation...
Johnson & Johnson is highlighted as a compelling dividend investment with a 2.02% yield, outperforming both its industry (1.93%) and the S&P 500 (1.41%). The company has increased its dividend annually over the past 5 years with an average increase of 5.37%, and maintains a sustainable 49% payout ratio. With solid...
Kenvue (KVUE) is highlighted as a smart high-yield dividend stock with a 4.68% dividend yield and 64 consecutive years of dividend increases, making it a Dividend King. The company, spun off from Johnson & Johnson three years ago, generates steady revenue from recession-resilient consumer healthcare brands like Tylenol...
XLV and IXJ are two healthcare ETFs with different approaches: XLV focuses on 60 U.S. S&P 500 healthcare stocks with a low 0.08% expense ratio and stronger recent returns, while IXJ offers broader global diversification with 110 holdings across multiple countries but charges a higher 0.38% expense ratio. The choice...
Eli Lilly's Immunology division generated $2.6 billion in revenues in H1 2026, up 9% year-over-year, representing 6.1% of total revenues. Led by Taltz, the portfolio is expanding through newer products like Ebglyss and Omvoh, plus strategic acquisitions of DICE, Morphic, and Merida to strengthen its pipeline across...
Headlines via Polygon.io. Links open the original publisher.